Group 1 - The company reported a revenue of RMB 4.446 billion for the year ending December 31, 2024, representing a year-on-year increase of 9.1% [1] - Net profit decreased to RMB 598 million, down 12.6% year-on-year [1] - Gross profit increased to RMB 1.329 billion, reflecting a year-on-year growth of 3.4% [1] Group 2 - The company operates 16 hospitals focused on oncology, including 4 tertiary hospitals and 12 secondary hospitals, with 2 additional tertiary hospitals under construction [1] - The company has enhanced its clinical capabilities, adding 1 national chest pain center and 6 provincial and municipal key specialties during the reporting period [1] - The company has a total of 86 high-level medical talents, including experts receiving special government allowances and leaders of various specialty societies, along with 1,236 senior medical professionals [1] Group 3 - The company achieved a patient satisfaction rate of 97.03% for the 2024 fiscal year, an increase of 0.91 percentage points from the previous year [2] - The company is innovating its medical service models and exploring strategic partnerships with commercial insurance companies to improve the medical payment system [2] - The company is integrating artificial intelligence (AI) technology in areas such as radiation therapy, imaging-assisted diagnosis, mobile nursing, and smart patient services to enhance efficiency and patient experience [2]
海吉亚医疗(06078)发布年度业绩 净利润5.98亿元 同比减少12.6%